Verovaccines
VEROVACCiNES GmbH is a biotechnology company specializing in the rapid development of animal vaccines using an integrated subunit vaccine platform based on recombinant strains of the yeast Kluyveromyces lactis. Their mission is to bring vaccines to registration quickly and offer advantages along the entire value chain from vaccine design to commercialization, with a focus on innovative solutions for animal health.
Industries
Nr. of Employees
small (1-50)
Products
Recombinant subunit vaccine candidate for bluetongue virus serotype 3 (BTV-3)
A recombinant subunit vaccine candidate generated against the BTV-3 outbreak using a yeast-based antigen expression approach; reported as produced within weeks and progressed toward dossier completion within nine months.
Recombinant subunit vaccine candidate for bluetongue virus serotype 3 (BTV-3)
A recombinant subunit vaccine candidate generated against the BTV-3 outbreak using a yeast-based antigen expression approach; reported as produced within weeks and progressed toward dossier completion within nine months.
Services
Custom animal vaccine development using yeast-based subunit platform
End-to-end development service for animal vaccines leveraging a recombinant yeast expression platform to generate and optimize antigen constructs, progress validation studies, and support regulatory dossier preparation for registration.
Custom animal vaccine development using yeast-based subunit platform
End-to-end development service for animal vaccines leveraging a recombinant yeast expression platform to generate and optimize antigen constructs, progress validation studies, and support regulatory dossier preparation for registration.
Expertise Areas
- Animal vaccine development
- Subunit vaccine design
- Recombinant protein expression in yeast
- Preclinical validation and species-specific testing
Key Technologies
- Recombinant yeast expression (Kluyveromyces lactis)
- Subunit vaccine technology
- Multivalent vaccine design
- Rapid vaccine construct generation